{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "BFLY",
  "name": "Butterfly Network, Inc.",
  "url": "https://orbyd.app/dossiers/BFLY/",
  "json_url": "https://orbyd.app/dossiers/BFLY.json",
  "status": "RECENTLY_EXITED",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "Butterfly Embedded chip-licensing story got marquee validation — Midjourney's up-to-$74M/5yr full-body scanner on 40 Ultrasound-on-Chip modules (2026-06-18) plus 2nd partner Aleph Neuro (2026-06-25). Fundamentals still accelerating, but the June double has stalled and news thinned; a binary Q2 print (~early Aug) is now the next input and the easy momentum leg is spent.",
  "invalidation_trigger": "A weekly close below $7.00 breaks the late-June Midjourney breakout base and opens the gap-fill toward the $5.70 shelf; secondary: a Q2 print below the $27M guide low end or a cut FY range, or continued insider distribution with no third Embedded license as social velocity flips to SATURATED.",
  "catalyst_date": "2026-08-06",
  "outcome": "PLAYED_OUT",
  "outcome_date": "2026-06-22",
  "invalidation_fired": false,
  "themes": [
    "medtech-diagnostics",
    "ai-chips-memory"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Q2 2026 earnings ~late July/early Aug (Q1 reported Apr 30); treat as binary — avoid fresh exposure into an unconfirmed print.",
    "Insider distribution is the main risk to the bull case: CBO Cashman sold ~$1.9M June 5-8 2026 (~20% of direct holding); Rothberg intent-to-sell 352k filed Jan 6. Watch for follow-on Form 4s.",
    "Highest-leverage unscheduled catalyst = a signed Butterfly Embedded chip-licensing deal (none dated); a HomeCare commercial agreement in H1 2026 is the secondary one.",
    "Emergent small-cap on social velocity, ~$1.27B cap, ~10-11x FY26 sales — assume two-sided gap risk, wide stop, probe sizing only.",
    "Theme ACCELERATING on fundamentals (rev +25%, Embedded +147%) but price stalled below the $5.72 high into insider selling — narrative and tape diverging.",
    "Q2 2026 earnings not yet dated; estimated ~early August 2026 (Q1 reported 2026-04-30). Treat as binary — avoid fresh exposure into an unconfirmed print; guide to beat is Q2 rev $27-31M.",
    "Midjourney economics (8-K 2025-11-17): up to $74M/5yr = $15M one-time + $10M/yr base + up to $9M milestones. Base ~$10M/yr is material but not transformational vs $117-121M FY revenue, and rides on Midjourney's pre-FDA screening business.",
    "Insider distribution is the key bear tell: Cashman sold ~$1.9M on 06-05/06-08 (~20% of direct holding); Rothberg intent-to-sell 352k filed 01-06; late-June Form 4 ownership shift. Watch follow-on Form 4s near the highs.",
    "Highest-leverage unscheduled catalyst = a signed follow-on Embedded license; Aleph Neuro (06-25) is the second partner proof-point after Midjourney (06-18).",
    "Parabolic +100% in ~3 weeks into the 52w high ($8.94) with 18% single-session whipsaws (−18.8% to $7.22 in late June). Probe sizing, wide stop, gap-fill risk back to the $5.70 shelf.",
    "Q2 2026 earnings not yet formally dated; estimated ~early August 2026 (Q1 reported 2026-04-30). Treat as binary — avoid fresh full-size exposure into an unconfirmed print. Bar to beat: Q2 rev $27-31M, FY $117-121M reaffirmed/raised, Embedded growth near +147% pace.",
    "Insider distribution is the key bear tell: CBO Cashman sold 399,461 sh (~$1.89M, ~20% of direct holding) on 2026-06-05/06-08 at ~$4.66-4.96; Rothberg intent-to-sell 352k filed 2026-01-06; insiders net sellers ~$6.2M TTM. Watch follow-on Form 4s near the highs.",
    "Highest-leverage unscheduled catalyst = a signed third Butterfly Embedded chip-licensing deal after Midjourney (2026-06-18) and Aleph Neuro (2026-06-25). Secondary = a HomeCare commercial agreement (H1 2026 target, now late).",
    "Midjourney economics (8-K 2025-11-17): up to $74M/5yr = $15M one-time + $10M/yr base + up to $9M milestones. Base ~$10M/yr is material but not transformational vs $117-121M FY revenue, and rides on Midjourney's pre-FDA whole-body screening business clearing FDA + reimbursement.",
    "Emergent small-cap on social velocity, ~$2B cap at the June highs, ~10-11x FY26 sales. 52w high $8.94, 18.8% single-session reversal to $7.22 in late June. Assume two-sided gap risk, wide stop, probe sizing only; gap-fill risk to the $5.70 shelf then the low-$4s base.",
    "Theme cooled from ACCELERATING to MATURING as of mid-July: fundamentals intact (rev +25%, Embedded +147%) but the June double has digested with no dated Embedded follow-on since 2026-06-25 and news flow thinned to generic index-mover baskets."
  ],
  "body_markdown": "## Current Thesis\nThe leg an investor is buying here is the re-rating of Butterfly from a handheld-ultrasound device vendor into an Ultrasound-on-Chip licensor. Butterfly Embedded (formerly Octiv) went from a line on the earnings deck to dated commercial proof inside eight days in late June: on 2026-06-18 Midjourney Medical unveiled a full-body tomographic scanner built on 40 Butterfly Ultrasound-on-Chip modules per system (~60-second whole-body scan) under a co-development/licensing deal worth up to $74M over five years (economics first filed in a Form 8-K 2025-11-17: $15M one-time + $10M annual license + up to $9M milestones), and on 2026-06-25 a second Embedded partner, Aleph Neuro, published 3D brain imaging on the same platform. That reframed the multiple story from a device comp to a software/royalty comp. The fundamental narrative is intact and still building, but the tape has moved ahead of it: shares doubled from the low-$4s in early June to a 52-week high of $8.94, whipsawed 18% intraday, and have spent the three weeks since digesting that move with no follow-on Embedded license and a news flow that has thinned to generic index-mover mentions (2026-07-06, 2026-07-07). The next real event is a binary Q2 print roughly three weeks out. The theme has cooled from ACCELERATING to MATURING — narrative valid, but the easy momentum leg is spent and the setup now waits on the print rather than leading it.\n\n## Bull Case\n- Midjourney Medical deal (announced 2026-06-18; economics filed 8-K 2025-11-17): up to $74M over five years, current prototype at 40 Ultrasound-on-Chip modules per system with future generations expected to use \"substantially more.\" Asset-light licensing revenue is what supports a software multiple over a hardware multiple.\n- Second Embedded validation within a week — Aleph Neuro 3D brain imaging (2026-06-25) — shows the chip generalizes past handheld ultrasound into tomographic and neuro imaging, signaling a licensing pipeline rather than a single marquee customer.\n- Q1 2026 (reported 2026-04-30): revenue $26.5M, +25% YoY, ~69% gross margin, Butterfly Embedded revenue +147% YoY. FY2026 guide reaffirmed at $117–121M (~20–24% growth); Q2 guided to $27–31M.\n- First FDA-cleared \"blind sweep\" AI guidance tool (Q1 2026) lets minimally-trained users capture diagnostic images, extending the addressable market into primary care, global health and home settings.\n- Balance sheet: ~$138M cash with low debt (latest filings) funds the Embedded build-out without near-term dilution pressure.\n- Loss narrowing: adjusted EBITDA loss $6.1M in Q1 versus $9.1M a year earlier — a trajectory that underwrites a re-rate if ~25% top-line growth holds through the Q2 print.\n\n## Bear Case\n- Insiders sold the first half of this move. Founder Jonathan Rothberg filed intent to sell 352k shares (2026-01-06); insiders were net sellers of ~$6.2M over the trailing year. Distribution into strength with no offsetting insider buying is the primary tell against the bull case.\n- The double ran on Midjourney headline flow plus retail social velocity on a ~$2B small-cap, punctuated by an 18.8% single-session reversal to $7.22 in late June. Reflexive spikes of that kind round-trip fast once the headline cadence pauses — and it has paused, with no dated Embedded follow-on since 2026-06-25.\n- The $74M contract spans five years (~$10M/yr base) — material against a $117–121M revenue base but not transformational per year, and contingent on Midjourney's unproven whole-body screening business clearing FDA and securing reimbursement. Benzinga (2026-06-18) flagged both hurdles explicitly.\n- Valuation carries no cushion into a miss: roughly 10–11x FY26 sales for a still-unprofitable name means a Q2 print at the low end of the $27–31M guide, or soft FY commentary, resets the multiple quickly.\n\n## Setup & Price Structure\nThe chart is a spent parabola working off its extension, not a fresh breakout. The June run took price from the low-$4s base to a 52-week high of $8.94 in about three weeks — a clean double — then printed an 18.8% reversal to $7.22, defining the immediate risk band. The Midjourney breakout base sits near $7.00; a hold above it keeps the re-rate structurally alive, while a loss of it opens the unfilled gap toward the $5.70 shelf, and beneath that the pre-Midjourney low-$4s launchpad. With the news flow thinned to generic \"stocks moving higher\" baskets (2026-07-06, 2026-07-07) and no follow-on license dated, momentum has decayed into a range rather than extended. For a name in this playbook, strength is the setup — but the strength has already been paid out and the next directional input is the print, not the tape. Fresh exposure ahead of that print is a probe at most; the higher-quality entry is a post-earnings continuation on a beat-and-hold above the base, or a reclaim off a lower gap-fill, not a chase of a stalled leg into binary risk.\n\n## Catalyst Calendar (next 30 days)\n- ~2026-08-06 (est.): Q2 2026 earnings — the binary. Q1 was reported 2026-04-30; Q2 typically lands late July/early August. Bar to clear: revenue in the guided $27–31M range, FY $117–121M reaffirmed or raised, and Butterfly Embedded revenue growth holding near the +147% Q1 pace. Avoid fresh full-size exposure into an unconfirmed print.\n- Unscheduled, highest-leverage: a signed follow-on Butterfly Embedded chip-licensing deal (a third partner after Midjourney and Aleph Neuro). None is dated; a signing would re-accelerate the theme and is the cleanest bull trigger.\n- Unscheduled, bearish watch: follow-on insider Form 4s near the highs — continued distribution after the Cashman/Rothberg sales would confirm the tape-vs-narrative divergence.\n- Secondary: a HomeCare commercial agreement, targeted for H1 2026 and now running late; any dated announcement widens the device story beyond the Embedded license.\n\n## What Would Change Our Mind\nThe bull structure stays intact while price holds the late-June base and the Embedded licensing cadence continues. Secondary breaks: a Q2 print below the $27M low end of guide or a cut to the $117–121M FY range; continued insider distribution into any strength with no offsetting Form 4 buying; or the theme flipping to SATURATED — social velocity rolling over with no third Embedded partner to refresh the story. On the upside, a signed third Embedded license, or a Q2 beat above $31M with raised FY guidance, restores the theme to ACCELERATING and reopens the parabolic case toward and through the $8.94 high.\n\n## Correlation Notes\nBFLY trades as a high-beta small-cap medtech riding two overlapping baskets. It moves with risk-on retail/small-cap momentum flow — it was grouped with QuantumScape and Bloom Energy in the 2026-06-19 \"on investors' radar\" basket and printed +31.3% alongside other high-momentum movers on 2026-06-18 — so it is sensitive to broad risk appetite and social-flow rotation. Its Embedded licensing angle also gives it secondary correlation to AI-silicon/semiconductor sentiment (it moved the same 2026-06-18 session as Micron and Marvell). Idiosyncratic catalyst days (Midjourney/Embedded headlines, the Q2 print) decouple it from SPY entirely, with single-session swings of 18–31%. Position sizing should assume two-sided gap risk and treat the name as a narrative-driven small-cap, not a market-tracking medtech.",
  "first_seen": "2026-06-11",
  "last_analyzed": "2026-07-18T08:37:55+00:00",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}